Australian and New Zealand Intensive Care Research Centre

3 in Phase 3

Quick facts

Phase 3 pipeline

Cryopreserved platelets · Hematology / Critical Care
Cryopreserved platelets are platelets that have been frozen and stored for extended periods, then thawed for transfusion to restore hemostatic function in patients with thrombocytopenia or platelet dysfunction.
Epoetin Alfa 40000 UNT/ML · Hematology
Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.
Liquid-stored platelets · Hematology / Critical Care
Liquid-stored platelets are platelets preserved in liquid storage solution at refrigerated temperatures to maintain hemostatic function for transfusion.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Australian and New Zealand Intensive Care Research Centre

What is Australian and New Zealand Intensive Care Research Centre's pipeline?

Australian and New Zealand Intensive Care Research Centre has 3 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Cryopreserved platelets, Epoetin Alfa 40000 UNT/ML, Liquid-stored platelets.

Sector hub: All tracked pharma companies